不可手术非转移性胰腺癌消融性SBRT的长期结局
该研究回顾性分析了88例不可手术非转移性胰腺癌患者接受消融性5次SBRT(BED10≥100 Gy)的长期结局,中位随访64.0个月,从诊断起中位OS为18.1个月,从SBRT起为15.6个月,3级胃肠道出血发生率4.5%,无≥4级毒性。结论认为该方案生存获益良好且毒性可接受。
要点
- 消融性5次SBRT(BED10≥100 Gy)在不可手术非转移性胰腺癌中显示良好生存。
- 从诊断起中位OS 18.1个月,从SBRT起15.6个月,3年OS率分别为26.1%和22.1%。
- 3级胃肠道出血发生率4.5%,未观察到≥4级毒性。
核心结论
- 消融性5次SBRT(BED10≥100 Gy)在不可手术非转移性胰腺癌中可获得良好生存和可接受的毒性。
研究设计与样本
- 回顾性分析了2016至2020年间88例接受CyberKnife金标呼吸追踪的消融性5次SBRT的不可手术非转移性胰腺癌患者的前瞻性登记数据。
- 队列包括55例男性和33例女性,中位年龄65岁(范围36-84岁),诊断时29例医学上不可手术,59例局部晚期胰腺癌。
- 82例接受50 Gy/5次,6例接受55 Gy/5次,中位大体肿瘤体积33.6 cm3(范围3.7-167.8)。
主要发现
- 中位随访64.0个月,从诊断起中位OS为18.1个月(95%CI 16.6-27.1),从SBRT起为15.6个月(95%CI 14.1-23.4)。
- 从诊断起1、2、3年OS率分别为73.9%、39.8%、26.1%,从SBRT起分别为64.0%、36.0%、22.1%。
- 医学上不可手术患者从诊断起中位OS为18.2个月(95%CI 17.0-37.1),局部晚期患者为17.1个月(95%CI 15.9-28.9)。
- 从SBRT起,医学上不可手术患者中位OS为16.2个月(95%CI 15.0-35.9),局部晚期患者为14.4个月(95%CI 11.0-23.7)。
- 4例(4.5%)发生3级胃肠道出血,未观察到≥4级毒性。
临床怎么用
- 对于不可手术非转移性胰腺癌,可考虑采用BED10≥100 Gy的消融性5次SBRT,并注意监测胃肠道出血毒性。
局限性
- 回顾性研究设计,样本量有限(88例),可能影响结果的普遍性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE/OBJECTIVE(S): To evaluate long-term outcomes and tolerability of ablative 5-fraction stereotactic body radiation therapy (SBRT) administering a biologically effective dose (BED10, α/β = 10) ≥ 100 Gy in patients with inoperable, non-metastatic pancreatic cancer (PC). MATERIALS/METHODS: We retrospectively reviewed a prospective registry of 88 patients with inoperable non-metastatic PC who underwent ablative 5-fraction SBRT using a CyberKnife with fiducial-based respiratory tracking between 2016 and 2020. The outcomes included overall survival (OS), progression-free survival (PFS), and treatment-related toxicity. RESULTS: The cohort included 55 men and 33 women (median age, 65 years; range, 36-84 years). At diagnosis, 29 patients were medically inoperable, and 59 had locally advanced PC (LAPC). SBRT was administered at 50 Gy/5 fractions in 82 patients and 55 Gy/5 fractions in 6 patients. The median gross tumor volume was 33.6 cm3 (range, 3.7-167.8). With a median follow-up of 64.0 months, the median OS (mOS) was 18.1 months (95 % confidence interval [CI], 16.6-27.1) from the time at diagnosis and 15.6 months (95 % CI, 14.1-23.4) from the start of SBRT. The 1-, 2-, and 3-year OS rates were 73.9 %, 39.8 %, and 26.1 % from diagnosis, and 64.0 %, 36.0 %, and 22.1 % from SBRT, respectively. The mOS from the time at diagnosis was 18.2 months (95 % CI, 17.0-37.1) for medically inoperable patients and 17.1 months (95 % CI, 15.9-28.9) for those with LAPC, with corresponding 1-, 2-, and 3-year OS rates of 86.2 %, 41.4 %, and 31.0 % vs. 67.8 %, 39.0 %, and 23.7 %, respectively. From the start of SBRT, corresponding mOS was 16.2 months (95 % CI, 15.0-35.9) for medically inoperable patients and 14.4 months (95 % CI, 11.0-23.7) for LAPC, with 1-, 2-, and 3-year OS rates of 75.9 %, 37.9 %, and 27.6 % vs. 57.6 %, 33.9 %, and 18.6 %, respectively. Grade 3 gastrointestinal bleeding occurred in four patients (4.5 %), with no grade ≥ 4 toxicities observed. CONCLUSION: Ablative 5-fraction SBRT with BED10 ≥ 100 Gy results in favorable survival and acceptable toxicity in inoperable, non-metastatic PC.
引用
- Cao BY, Zhang LT, Wu CC, et al. Long-Term outcomes of ablative stereotactic body radiation therapy for inoperable, non-metastatic pancreatic cancer. Radiother Oncol. 2025. PMID: 41110804. doi:10.1016/j.radonc.2025.111210
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。